BD (Becton, Dickinson and Company) announced the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector, according to a press release from the company.
This research to evaluate the performance of the 5 mL BD Libertas device in people, including tissue effects, skin reactivity and patient acceptance, found that the BD Libertas device delivered, within an acceptable time period, 5 mL of 8 cP injections to the abdomen and thigh regardless of subject age, gender, or BMI and with/without patient movement.
The subcutaneous drug delivery system, currently in final phases of development, is designed as ready to use and to deliver drugs such as biologics with viscosities up to 50 cP in 2-5 mL and 5-10 mL configurations.
The application use, and removal of the injector were found to be acceptable, and 100 percent of subjects were likely to use the BD Libertas Wearable Injector if prescribed. No severe wheal, erythema, or bleeding was observed, and no unacceptable pain was noted at 24 hours post-injection.
